Behind-the-counter statins: a silver bullet for reducing costs and increasing access?
- PMID: 22091792
- PMCID: PMC3447239
- DOI: 10.1111/j.1475-6773.2011.01315.x
Behind-the-counter statins: a silver bullet for reducing costs and increasing access?
Abstract
Objective: To examine how the 2004 introduction of behind-the-counter (BTC) simvastatin in the United Kingdom affected utilization, prices, and expenditures.
Data sources/study setting: Secondary data on simvastatin utilization, prices, and expenditures between 1997 and 2007 in the United Kingdom and four other countries.
Study design: We used a difference-in-differences approach to estimate how the introduction of BTC simvastatin affected utilization, prices, and expenditures. This approach compares outcomes in the United Kingdom before and after the introduction of BTC simvastatin, using outcomes in countries where the drug remained prescription only to control for possible confounders.
Data collection/extraction methods: Data on simvastain utilization, prices, and expenditures between 1997 and 2007 in the United Kingdom and four other countries were obtained from an outside vendor.
Principal findings: The introduction of BTC simvastatin in the United Kingdom led to a significant increase in utilization of simvastatin and a significant decline in expenditures for simvastatin purchases. Our results are robust to alternate model specifications.
Conclusions: Behind-the-counter statins have the potential to simultaneously increase use of statins and lower expenditures.
© Health Research and Educational Trust.
Figures
Similar articles
-
Over-the-counter statins.Lancet. 2004 Jul 31-Aug 6;364(9432):411. doi: 10.1016/S0140-6736(04)16750-0. Lancet. 2004. PMID: 15288726 No abstract available.
-
Comparison of prescription drug costs in the United States and the United Kingdom, Part 1: statins.Pharmacotherapy. 2012 Jan;32(1):1-6. doi: 10.1002/PHAR.1005. Pharmacotherapy. 2012. PMID: 22392823
-
Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):323-30. doi: 10.1586/14737167.2015.967221. Epub 2014 Oct 23. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25338546
-
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.Clin Pharmacokinet. 2008;47(7):463-74. doi: 10.2165/00003088-200847070-00003. Clin Pharmacokinet. 2008. PMID: 18563955 Review.
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
Cited by
-
The Causal-Benefit Model to Prevent Cardiovascular Events.JACC Adv. 2024 Jan 22;3(3):100825. doi: 10.1016/j.jacadv.2023.100825. eCollection 2024 Mar. JACC Adv. 2024. PMID: 38938840 Free PMC article. Review.
-
With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs?Curr Cardiol Rep. 2023 May;25(5):423-430. doi: 10.1007/s11886-023-01861-2. Epub 2023 Mar 27. Curr Cardiol Rep. 2023. PMID: 36971960 Review.
-
Over-the-counter medicines: Global perspective and Indian scenario.J Postgrad Med. 2020 Jan-Mar;66(1):28-34. doi: 10.4103/jpgm.JPGM_381_19. J Postgrad Med. 2020. PMID: 31898596 Free PMC article. Review.
References
-
- Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-term Clinical and Economic Outcomes of a Community Pharmacy Diabetes Care Program. Journal of American Pharmaceutical Association. 2003;43:173–84. - PubMed
-
- Dhippayom T, Walker R. Impact of the Reclassification of Omeprazole on the Prescribing and Sales of Ulcer Healing Drugs. Pharmacy World & Science. 2006;28(4):194–8. - PubMed
-
- Filion KB, Delaney JA, Brophy JM, Ernst P, Suissa S. The Impact of Over-the-Counter Simvastatin on the Number of Statin Prescriptions in the United Kingdom: A View from the General Practice Research Database. Pharmacoepidemiology and Drug Safety. 2007;16(1):1–4. - PubMed
-
- Freudenheim M. Claritin's Price Falls, But Drug Costs More. The New York Times. 2003 [accessed on August 18, 2011]. Available at: http://www.nytimes.com/2003/05/08/business/claritin-s-price-falls-but-dr....
-
- Furler MD, Rolnick MS, Lawday KS, Mak MW, Einarson TR. Cost Impact of Switching Histamine(2)-Receptor Antagonists to Nonprescription Status. Annals of Pharmacotherapy. 2002;36(7–8):1135–41. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
